ADARx Pharmaceuticals priced its IPO at $446.3 million and begins trading on Nasdaq under the ticker ADRX, continuing a busy year for RNA-focused public-market debuts. The company sold more than 26 million shares at $17 each, and separately secured additional funding from AbbVie. ADARx’s lead program onvuzosiran is in late-stage testing for hereditary angioedema, while the company is also advancing agazisiran across additional indications. The IPO also highlights ongoing investor interest in RNA interference platforms beyond liver-only targets. For the sector, the listing adds another highly capitalized player aimed at expanding delivery and potency improvements for constrained RNA modalities.